Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 22, 2007
Issued Date -
N/A
app pub date -
May 12, 1997
filing date -
Mar 17, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core.sub.131-140; SEQ ID NO:1), LLALLSCLTV (Core.sub.178-187; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS3.sub.1169-1177; SEQ ID NO:26), KLVALGINAV (NS3.sub.1406-1415; SEQ ID NO:28), SLMAFTAAV (NS4.sub.1789-1797; SEQ ID NO:34), LLFNILGGWV (NS4.sub.1807-1816; SEQ ID NO:35), and ILDSFDPLV (NS5.sub.2252-2260; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully